In Liu et al.’s (2019) study [39], GLP-1 RAs were found to have minimal impact on hard endpoints, such as end-stage renal disease, but dramatically decrease the course of albuminuria and exhibit trends toward a slower drop in eGFR. This evidence concerns the gene GLP1R and stage 5 chronic kidney disease.